Simultaneous care in oncology: Assessment of benefit in relation to symptoms, sex, and age in 753 patients.
advanced cancer
early palliative care (EPC)
end of life chemotherapy
patient-centered care
simultaneous care
symptom assessment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
07
2022
accepted:
05
09
2022
entrez:
31
10
2022
pubmed:
1
11
2022
medline:
1
11
2022
Statut:
epublish
Résumé
Early activation of palliative care for patients with advanced cancer is central in the treatment trajectory. At the Veneto Institute of Oncology, a simultaneous-care outpatient clinic (SCOC) has been active since 2014, where patients are evaluated by an oncologist together with a palliative care team. Recently, we reported on consecutive patients admitted at SCOC from 2018 to 2021 in terms of appropriateness, process, and outcome indicators. Here, we report further analysis in the same group of 753 patients, evaluating other parameters and the correlation between symptom intensity, gender, age, and survival. SCOC data were retrieved from a prospectively maintained database. Among the patients, 42.2% were women, and the median age was 68 years, with 46.7% of patients aged ≥70 years. The most prevalent disease type was gastrointestinal cancer (75.2%), and 90.9% of the patients had metastatic disease. The median score for the distress thermometer was 4; the vast majority of the patients (98.6%) reported physical problems, and 69.4% presented emotional issues. Younger women demonstrated a significantly greater median distress than other patients (p=0.0018). Almost all symptoms had a higher prevalence on the 0-3 Edmonton Symptom Assessment Scale (ESAS) score, except for fatigue. About 43.8% of the patients received systemic anticancer treatment (SAT) in the last 60 days of life, 15.0% of whom received SAT in the last month and 3.1% in the last 2 weeks. For some symptoms, women frequently had more ESAS >3. Pain and nausea were significantly less reported by older patients compared with younger adults. Men had a lower risk of having MUST score ≥ 2 (p=0.0311). Men and older patients showed a lower prognosis awareness (p=0.0011 and p=0.0049, respectively). Older patients received less SAT within the last 30 days of life (p=0.0006) and had death risk decreased by 20.0%. Our study identified two subgroups of patients with advanced cancer who require special attention and support due to important symptoms' burden detected by Patient Reported Outcome Measures tests: women and younger adults. These categories of patients require special attention and should be provided early access at SCOC. The role of an oncologist remains crucial to intercept all patients in need of early palliative care and balancing trade-offs of anticancer treatment in advanced metastatic disease.
Sections du résumé
Background
UNASSIGNED
Early activation of palliative care for patients with advanced cancer is central in the treatment trajectory. At the Veneto Institute of Oncology, a simultaneous-care outpatient clinic (SCOC) has been active since 2014, where patients are evaluated by an oncologist together with a palliative care team. Recently, we reported on consecutive patients admitted at SCOC from 2018 to 2021 in terms of appropriateness, process, and outcome indicators. Here, we report further analysis in the same group of 753 patients, evaluating other parameters and the correlation between symptom intensity, gender, age, and survival.
Methods
UNASSIGNED
SCOC data were retrieved from a prospectively maintained database.
Results
UNASSIGNED
Among the patients, 42.2% were women, and the median age was 68 years, with 46.7% of patients aged ≥70 years. The most prevalent disease type was gastrointestinal cancer (75.2%), and 90.9% of the patients had metastatic disease. The median score for the distress thermometer was 4; the vast majority of the patients (98.6%) reported physical problems, and 69.4% presented emotional issues. Younger women demonstrated a significantly greater median distress than other patients (p=0.0018). Almost all symptoms had a higher prevalence on the 0-3 Edmonton Symptom Assessment Scale (ESAS) score, except for fatigue. About 43.8% of the patients received systemic anticancer treatment (SAT) in the last 60 days of life, 15.0% of whom received SAT in the last month and 3.1% in the last 2 weeks. For some symptoms, women frequently had more ESAS >3. Pain and nausea were significantly less reported by older patients compared with younger adults. Men had a lower risk of having MUST score ≥ 2 (p=0.0311). Men and older patients showed a lower prognosis awareness (p=0.0011 and p=0.0049, respectively). Older patients received less SAT within the last 30 days of life (p=0.0006) and had death risk decreased by 20.0%.
Conclusion
UNASSIGNED
Our study identified two subgroups of patients with advanced cancer who require special attention and support due to important symptoms' burden detected by Patient Reported Outcome Measures tests: women and younger adults. These categories of patients require special attention and should be provided early access at SCOC. The role of an oncologist remains crucial to intercept all patients in need of early palliative care and balancing trade-offs of anticancer treatment in advanced metastatic disease.
Identifiants
pubmed: 36313660
doi: 10.3389/fonc.2022.989713
pmc: PMC9614371
doi:
Types de publication
Journal Article
Langues
eng
Pagination
989713Informations de copyright
Copyright © 2022 Galiano, Schiavon, Nardi, Guglieri, Pambuku, Martino, Bolshinsky, Murgioni, Intini, Soldà, Marino, Daniel, De Toni, Pittarello, Chiusole, Prete, Bimbatti, Nappo, Caccese, Bergamo, Brunello, Lonardi and Zagonel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Jpn J Clin Oncol. 2020 Jun 10;50(6):693-700
pubmed: 32303764
Nihon Koshu Eisei Zasshi. 2017;64(1):3-13
pubmed: 28228632
J Clin Oncol. 2015 May 1;33(13):1438-45
pubmed: 25800768
Int J Qual Health Care. 2005 Dec;17(6):505-9
pubmed: 15985505
Front Psychol. 2021 Aug 27;12:704590
pubmed: 34512460
BMC Palliat Care. 2022 Feb 7;21(1):20
pubmed: 35125092
Cancers (Basel). 2022 May 23;14(10):
pubmed: 35626172
JAMA Oncol. 2017 Jul 01;3(7):961-968
pubmed: 28253393
J Cancer Res Clin Oncol. 2018 Aug;144(8):1591-1599
pubmed: 29845418
JAMA Oncol. 2022 May 1;8(5):681-682
pubmed: 35297961
JAMA Oncol. 2015 Sep;1(6):778-84
pubmed: 26203912
Cancer. 1998 May 15;82(10):1904-8
pubmed: 9587123
Psychooncology. 2001 Jan-Feb;10(1):19-28
pubmed: 11180574
J Pain Symptom Manage. 2007 Apr;33(4):389-97
pubmed: 17397700
Cancers (Basel). 2022 May 19;14(10):
pubmed: 35626114
J Clin Oncol. 2018 Apr 10;36(11):1096-1102
pubmed: 29474102
Oncologist. 2006 Nov-Dec;11(10):1095-9
pubmed: 17110629
Cancers (Basel). 2022 Jan 11;14(2):
pubmed: 35053493
Ann Palliat Med. 2015 Jul;4(3):156-61
pubmed: 26231812
Cancers (Basel). 2022 Feb 18;14(4):
pubmed: 35205793
Cancer Med. 2022 Apr;11(8):1869-1878
pubmed: 35142091
JCO Clin Cancer Inform. 2022 Mar;6:e2100163
pubmed: 35467965
Eur J Cancer. 2016 Sep;65:61-8
pubmed: 27472648
Lancet Oncol. 2016 Dec;17(12):e552-e559
pubmed: 27924753
Curr Treat Options Oncol. 2021 Apr 8;22(5):44
pubmed: 33830352
ESMO Open. 2018 Jul 11;3(5):e000372
pubmed: 30018816
Lancet Oncol. 2018 Nov;19(11):e588-e653
pubmed: 30344075
J Clin Oncol. 2016 Jan 20;34(3):259-67
pubmed: 26644532
Clin Nutr. 2004 Oct;23(5):1104-12
pubmed: 15380902
J Clin Oncol. 2017 Jan;35(1):96-112
pubmed: 28034065
J Clin Oncol. 2012 Feb 1;30(4):394-400
pubmed: 22203758
J Natl Compr Canc Netw. 2022 Jan;20(1):96-98
pubmed: 34991072
J Natl Compr Canc Netw. 2012 Oct 1;10(10):1284-309
pubmed: 23054879
Ann Oncol. 2015 Sep;26(9):1953-1959
pubmed: 26088196
J Pain Symptom Manage. 2017 Mar;53(3):630-643
pubmed: 28042071
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
Oncologist. 2016 Jan;21(1):119-26
pubmed: 26621041
Lancet. 2014 May 17;383(9930):1721-30
pubmed: 24559581
Eur J Cancer. 2016 Dec;69:110-118
pubmed: 27821313
J Palliat Care. 2020 Jan;35(1):3-7
pubmed: 30871411
JAMA. 2016 Jan 19;315(3):284-92
pubmed: 26784776
J Palliat Care. 1991 Summer;7(2):6-9
pubmed: 1714502
J Natl Cancer Inst. 2013 Oct 2;105(19):1432-40
pubmed: 24047960
J Clin Oncol. 2004 Jan 15;22(2):315-21
pubmed: 14722041
J Adv Pract Oncol. 2019 Mar;10(2):175-179
pubmed: 31538028
Cochrane Database Syst Rev. 2017 Jun 12;6:CD011129
pubmed: 28603881
BMC Cancer. 2022 Feb 10;22(1):161
pubmed: 35144569
BMC Palliat Care. 2011 Sep 21;10:14
pubmed: 21936940
ESMO Open. 2022 Apr;7(2):100457
pubmed: 35366489
Clin Nutr. 2021 May;40(5):2898-2913
pubmed: 33946039
Cancers (Basel). 2022 Jan 31;14(3):
pubmed: 35159013
Int J Environ Res Public Health. 2020 Dec 24;18(1):
pubmed: 33374440
BMC Palliat Care. 2018 Jul 23;17(1):96
pubmed: 30037346
Am J Hosp Palliat Care. 2022 Nov;39(11):1337-1341
pubmed: 35317656
Tumori. 2017 Jan 21;103(1):9-14
pubmed: 28009422
Ann Oncol. 2003 Sep;14(9):1335-7
pubmed: 12954570
Ann Oncol. 2011 Nov;22(11):2375-2380
pubmed: 21402621
BMJ Open. 2022 May 6;12(5):e057437
pubmed: 35523497
Nat Rev Clin Oncol. 2016 Mar;13(3):159-71
pubmed: 26598947